Mission Wealth Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$516K Buy
2,387
+766
+47% +$147K 0.01% 676
2026
Q1
$297K Sell
1,621
-201
-11% -$37K 0.01% 609
2025
Q4
$321K Buy
1,822
+92
+5% +$15K 0.01% 598
2025
Q3
$242K Sell
1,730
-126
-7% -$17K ﹤0.01% 630
2025
Q2
$233K Buy
1,856
+6
+0.3% +$748 0.01% 625
2025
Q1
$253K Sell
1,850
-471
-20% -$67.3K 0.01% 588
2024
Q4
$355K Buy
2,321
+254
+12% +$42.8K 0.01% 516
2024
Q3
$401K Buy
2,067
+154
+8% +$32.2K 0.01% 474
2024
Q2
$443K Buy
1,913
+87
+5% +$18.9K 0.01% 439
2024
Q1
$394K Buy
1,826
+66
+4% +$15.5K 0.01% 489
2023
Q4
$455K Sell
1,760
-16
-0.9% -$3.93K 0.01% 390
2023
Q3
$456K Buy
1,776
+184
+12% +$49.2K 0.02% 359
2023
Q2
$453K Sell
1,592
-3
-0.2% -$893 0.02% 360
2023
Q1
$443K Buy
1,595
+26
+2% +$7.19K 0.02% 364
2022
Q4
$434K Buy
1,569
+64
+4% +$18.1K 0.02% 348
2022
Q3
$402K Sell
1,505
-38
-2% -$8.07K 0.02% 335
2022
Q2
$315K Sell
1,543
-97
-6% -$19.8K 0.02% 385
2022
Q1
$345K Sell
1,640
-156
-9% -$33.9K 0.02% 384
2021
Q4
$431K Buy
+1,796
New +$462K 0.02% 350

Other funds holding BIIB

Mission Wealth Management's BIIB Position: Q2 2026 in Review

Mission Wealth Management increased its Biogen (BIIB) stake by 47% in Q2 2026, buying an estimated $147K and bringing the position to 2,387 shares worth $516K. The position accounts for 0.01% of the portfolio, ranked #676.

Mission Wealth Management first reported a position in BIIB in Q4 2021 and has held it in 19 quarters since. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Mission Wealth Management held 2,387 shares of Biogen worth $516K as of Q2 2026.
  • Mission Wealth Management bought 766 Biogen shares in Q2 2026, an estimated $147K.
  • Biogen made up 0.01% of Mission Wealth Management's portfolio in Q2 2026, its #676 holding.
  • Mission Wealth Management first reported a position in Biogen in Q4 2021 and has held it in 19 quarters since.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Mission Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.